Carter Gould
Stock Analyst at Cantor Fitzgerald
(3.93)
# 585
Out of 5,131 analysts
218
Total ratings
58.14%
Success rate
8.03%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Overweight | $135 → $155 | $154.98 | +0.01% | 17 | Feb 11, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $985 → $1,205 | $1,040.00 | +15.87% | 15 | Feb 5, 2026 | |
| PFE Pfizer | Reiterates: Neutral | $27 | $27.58 | -2.10% | 17 | Feb 4, 2026 | |
| MRK Merck & Co. | Maintains: Neutral | $116 → $120 | $121.41 | -1.16% | 12 | Feb 4, 2026 | |
| AMGN Amgen | Maintains: Neutral | $315 → $350 | $369.19 | -5.20% | 19 | Feb 4, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $740 → $800 | $803.17 | -0.39% | 22 | Feb 2, 2026 | |
| NUVL Nuvalent | Maintains: Overweight | $100 → $112 | $100.89 | +11.01% | 2 | Oct 31, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $245 → $250 | $231.50 | +7.99% | 18 | Oct 9, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $485 | $491.47 | -1.32% | 4 | Aug 5, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $55 | $60.74 | -9.45% | 16 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $54.10 | - | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $160 → $165 | $124.12 | +32.94% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $27.82 | -28.11% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $196.52 | -8.41% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $60 | $12.78 | +369.48% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $0.63 | +376.95% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.65 | +445.45% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $66.26 | +43.37% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $5.70 | +250.88% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $68.50 | +6.57% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $1.87 | +541.71% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $2.29 | -34.50% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $125.31 | +203.25% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $101.10 | -18.89% | 5 | Jan 16, 2019 |
Gilead Sciences
Feb 11, 2026
Maintains: Overweight
Price Target: $135 → $155
Current: $154.98
Upside: +0.01%
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $985 → $1,205
Current: $1,040.00
Upside: +15.87%
Pfizer
Feb 4, 2026
Reiterates: Neutral
Price Target: $27
Current: $27.58
Upside: -2.10%
Merck & Co.
Feb 4, 2026
Maintains: Neutral
Price Target: $116 → $120
Current: $121.41
Upside: -1.16%
Amgen
Feb 4, 2026
Maintains: Neutral
Price Target: $315 → $350
Current: $369.19
Upside: -5.20%
Regeneron Pharmaceuticals
Feb 2, 2026
Maintains: Overweight
Price Target: $740 → $800
Current: $803.17
Upside: -0.39%
Nuvalent
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $112
Current: $100.89
Upside: +11.01%
AbbVie
Oct 9, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $231.50
Upside: +7.99%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Overweight
Price Target: $535 → $485
Current: $491.47
Upside: -1.32%
Bristol-Myers Squibb Company
Apr 23, 2025
Reiterates: Neutral
Price Target: $55
Current: $60.74
Upside: -9.45%
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $54.10
Upside: -
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $124.12
Upside: +32.94%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $27.82
Upside: -28.11%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $196.52
Upside: -8.41%
Aug 14, 2024
Maintains: Overweight
Price Target: $200 → $60
Current: $12.78
Upside: +369.48%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $0.63
Upside: +376.95%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.65
Upside: +445.45%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $66.26
Upside: +43.37%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $5.70
Upside: +250.88%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $68.50
Upside: +6.57%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $1.87
Upside: +541.71%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $2.29
Upside: -34.50%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $125.31
Upside: +203.25%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $101.10
Upside: -18.89%